23andMe Holding Co - Ordinary Shares - Class A

NASDAQ:ME   4:00:00 PM EDT
-0.09 (-3.95%)
7:34:48 PM EDT: $2.18 -0.01 (-0.46%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.00B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$88.4 Million
Adjusted EPS-$0.16
See more estimates
10-Day MA$2.28
50-Day MA$2.47
200-Day MA$2.85
See more pivots

23andMe Holding Co - Ordinary Shares - Class A Stock, NASDAQ:ME

349 Oyster Point Boulevard, South San Francisco, California 94080
United States of America
Phone: +1.650.938.6300
Number of Employees: 768


23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. It provides direct access to genetic information with multiple Food and Drug Administration authorizations for genetic health risk reports. The company operates under the Consumer and Research Services segment, and the Therapeutics segment. The firmâ??s research platform has generated publications on the genetic underpinnings of a range of diseases, conditions, and traits. The platform also powers the 23andMe therapeutics group, pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in South San Francisco, CA.